Cevimeline

From Wikipedia, the free encyclopedia
Cevimeline
Cevimeline.svg
Cevimeline 3D.png
Clinical data
Trade namesEvoxac
AHFS/Drugs.comMonograph
MedlinePlusa608025
Pregnancy
category
  • C
Routes of
administration
By mouth (capsules)
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding<20%
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H17NOS
Molar mass199.31 g·mol−1
3D model (JSmol)
 ☒NcheckY (what is this?)  

Cevimeline (trade name Evoxac) is a parasympathomimetic and muscarinic agonist,[1] with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth and especially associated with Sjögren's syndrome.

Mechanism of action[]

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects[]

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[2]

Contraindications include asthma and angle closure glaucoma.[citation needed]

See also[]

  • Pilocarpine — a similar parasympathomimetic medication for dry mouth (xerostomia)
  • Bethanechol — a similar muscarinic parasympathomimetic with longer-lasting effect

References[]

  1. ^ Ono M, Takamura E, Shinozaki K, et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277.
  2. ^ [1] MedicineNet: Cevimeline. Accessed 10/12/2007

External links[]

Retrieved from ""